Post-Marketing Progress: Drug Industry Is Meeting Phase IV Commitments, FDA Says
This article was originally published in RPM Report
FDA’s John Jenkins disputes accusations that the pharmaceutical industry does not take post-marketing studies seriously and that the agency is lax on enforcement. According to updated data from FDA, Phase IV studies are being completed in a timely manner, Jenkins argues – and when they aren’t, the agency is taking action.
You may also be interested in...
Post-Marketing Commitments: FDA’s Revised Metric Paints Bleaker Picture
Compliance rates for post-marketing requirement and commitment reporting drop when FDA takes annual reports into consideration.
FDAAA Impact Analysis (Year 5): The REMS Paradox
FDA is approving new molecules at the fastest rate of the REMS era, while actually imposing REMS obligations less frequently than ever. That is good news for sponsors—but it doesn’t make a lot of sense if the REMS are working as intended. After five years, the role of REMS is still very much a work in progress.
Merck’s Postmarketing Study Delays Prompt FDA To Unsheathe New Enforcement Power
Januvia and Janumet are misbranded, FDA tells Merck in a warning letter noting that rodent safety studies for the sitagliptin diabetes drugs were 20 months behind schedule. The letter marks the first time FDA has used its FDAAA powers to take enforcement action against a pharma company for such a delay.